Outcome of patients older than 80 years with diffuse large B‐cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|84-92

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 84-92

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment decisions and outcome in very elderly patients with diffuse large B-Cell lymphoma

By Fabbri Alberto   Cencini Emanuele   Bocchia Monica  

Cancer, Vol. 121, Iss. 20, 2015-10 ,pp. : 3746-3747

Blackwell Publishing

Access to resources Recommend Favorite

Reply to treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma

By Williams Jessica N.   Koff Jean L.   Flowers Christopher R.  

Cancer, Vol. 121, Iss. 20, 2015-10 ,pp. : 3748-3748

Blackwell Publishing

Access to resources Recommend Favorite

Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP

By  

Current Cancer Drug Targets, Vol. 14, Iss. 7, 2014-09 ,pp. : 659-670

Bentham Science Publishers

Access to resources Recommend Favorite

Novel agents for diffuse large B-cell lymphoma

By Sinha Rajni   DeJoubner Nutan   Flowers Christopher  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 5, 2011-05 ,pp. : 669-680

Informa Healthcare

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of the Addition of Rituximab to CHOP in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma

By Ferrara Felicetto  

Clinical Drug Investigation, Vol. 28, Iss. 1, 2008-01 ,pp. : 55-65

Adis International

Access to resources Recommend Favorite